This trial is evaluating a cancer vaccine strategy for EGFR and/or HER2 bearing tumors in dogs. This stage of the project is simply to determine if anti-tumor antibodies arise in vaccinated animals. The vaccine is composed of a short peptide of canine EGFR (15 amino acids) mixed with LymeVax(R) (Zoetis) and mineral oil. The patient gets two 0.5 cc vaccines (SC in the nape of the neck) separated by 3 weeks regardless of the size of the dog. Blood samples will be taken at the time of the first injection (Day 0), Day 21 (time of the booster injection), Day 28 (+/- 3 -4 days) and Day 56 (+/- 7 days). Based upon mouse studies, we expect no untoward effects or even injection site reactions. There are NO contraindications with other forms of therapy, either surgical or chemotherapy. We would prefer mammary tumors and osteosarcomas (and other tumors that are presumed to express EGFR and /or HER2).
any dog with confirmed mammary cancer or osteosarcoma
dogs with any other confirmed cancer may be eligible depending upon enrollment
No steroids given within 7 days
Performance score of 0, 1, or 2-expected survival time of over 6 weeks
Dogs less than 3 kg in body weight
Prior steroid use
Other clinical findings precluding the use of a vaccine